In a subgroup of high-risk asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events

Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/ day) in reducing cardiovascular events. Clinicians in Asia doubt...

Full description

Bibliographic Details
Main Authors:	Chaithiraphan, S. (Author), Chen, J.-H (Author), Dans, A.L (Author), Gao, P. (Author), Jae-Hyung, K. (Author), Lisheng, L. (Author), Teo, K. (Author), Yusoff, K. (Author), Yusuf, S. (Author), Zhu, J. (Author)
Format:	Article
Language:	English
Subjects:	acute heart infarction adult aged angioneurotic edema Angiotensin-Converting Enzyme Inhibitors article Asia Asian benzimidazole derivative Benzimidazoles Benzoates benzoic acid derivative body mass Body Mass Index cardiovascular disease Cardiovascular Diseases cause of death cerebrovascular accident clinical trial congestive heart failure controlled clinical trial controlled study coughing dipeptidyl carboxypeptidase inhibitor dose response double blind procedure Double-Blind Method drug dose titration drug efficacy drug safety drug tolerability drug withdrawal ethnic group Ethnic Groups ethnicity ethnology female heart protection high risk patient hospitalization human Humans hypotension major clinical study male mortality multicenter study patient compliance Patient Compliance placebo Placebos race difference ramipril Ramipril randomized controlled trial risk Risk syncope telmisartan treatment outcome Treatment Outcome
Online Access:	View Fulltext in Publisher View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

In a subgroup of high-risk asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events

Internet

Similar Items